FindTrial
Sign In

Short-term efficacy and safety of perioperative SARS-CoV-2 infection in patients with hepatobiliary malignancies: A real-world study

Short-term efficacy and safety of perioperative SARS-CoV-2 infection in patients with hepatobiliary malignancies: A real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068187
Enrollment
Unknown
Registered
2023-02-09
Start date
2023-02-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatobiliary malignancy

Interventions

COVID-19 infection group:N/A
Non COVID-19 infection group:N/A

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years, gender is not limited, volunteer to participate in the study;2. Patients with operable hepatobiliary malignancies;3. ECOG 0 or 1

Exclusion criteria

Exclusion criteria: Important clinical data missing

Design outcomes

Primary

MeasureTime frame
Safety;Complication;—

Secondary

MeasureTime frame
Disease free survival;—

Countries

China

Contacts

Public ContactWang Hongguang

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

wanghongguang301@163.com15601170661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026